Abstract:Objective: Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds will seek medical attention. For the purposes of this guideline, we define the target patient with a nosebleed as a patient with bleeding from the nostril, nasal cavity, or nasopharynx that is sufficient to warrant medical advice or care. This includes bleeding that is severe, persistent, and/or recurrent, as well as bleeding that impacts a patient's quality of life. Interventions for nosebleeds range from self-treatment and home remedies to more intensive procedural interventions in medical offices, emergency departments, hospitals, and operating rooms. Epistaxis has been estimated to account for 0.5% of all emergency department visits and up to one-third of all otolaryngology-related emergency department encounters. Inpatient hospitalization for aggressive treatment of severe nosebleeds has been reported in 0.2% of patients with nosebleeds. Purpose: The primary purpose of this multidisciplinary guideline is to identify quality improvement opportunities in the management of nosebleeds and to create clear and actionable recommendations to implement these opportunities in clinical practice. Specific goals of this guideline are to promote best practices, reduce unjustified variations in care of patients with nosebleeds, improve health outcomes, and minimize the potential harms of nosebleeds or interventions to treat nosebleeds. The target patient for the guideline is any individual aged ≥3 years with a nosebleed or history of nosebleed who needs medical treatment or seeks medical advice. The target audience of this guideline is clinicians who evaluate and treat patients with nosebleed. This includes primary care providers such as family medicine physicians, internists, pediatricians, physician assistants, and nurse practitioners. It also includes specialists such as emergency medicine providers, otolaryngologists, interventional radiologists/neuroradiologists and neurointerventionalists, hematologists, and cardiologists. The setting for this guideline includes any site of evaluation and treatment for a patient with nosebleed, including ambulatory medical sites, the emergency department, the inpatient hospital, and even remote outpatient encounters with phone calls and telemedicine. Outcomes to be considered for patients with nosebleed include control of acute bleeding, prevention of recurrent episodes of nasal bleeding, complications of treatment modalities, and accuracy of diagnostic measures. This guideline addresses the diagnosis, treatment, and prevention of nosebleed. It focuses on nosebleeds that commonly present to clinicians via phone calls, office visits, and emergency room encounters. This guideline discusses first-line treatments such as nasal compression, application of vasoconstrictors, nasal packing, and nasal cautery. It also addresses more complex epistaxis management, which includes the use of endoscopic arterial ligation and interventional radiology procedures. Management options for 2 special groups of patients-patients with hereditary hemorrhagic telangiectasia syndrome and patients taking medications that inhibit coagulation and/or platelet function-are included in this guideline. This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group. It is not intended to be a comprehensive, general guide for managing patients with nosebleed. In this context, the purpose is to define useful actions for clinicians, generalists, and specialists from a variety of disciplines to improve quality of care. Conversely, the statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients. Action statements: The guideline development group made recommendations for the following key action statements: (1) At the time of initial contact, the clinician should distinguish the nosebleed patient who requires prompt management from the patient who does not. (2) The clinician should treat active bleeding for patients in need of prompt management with firm sustained compression to the lower third of the nose, with or without the assistance of the patient or caregiver, for 5 minutes or longer. (3a) For patients in whom bleeding precludes identification of a bleeding site despite nasal compression, the clinician should treat ongoing active bleeding with nasal packing. (3b) The clinician should use resorbable packing for patients with a suspected bleeding disorder or for patients who are using anticoagulation or antiplatelet medications. (4) The clinician should educate the patient who undergoes nasal packing about the type of packing placed, timing of and plan for removal of packing (if not resorbable), postprocedure care, and any signs or symptoms that would warrant prompt reassessment. (5) The clinician should document factors that increase the frequency or severity of bleeding for any patient with a nosebleed, including personal or family history of bleeding disorders, use of anticoagulant or antiplatelet medications, or intranasal drug use. (6) The clinician should perform anterior rhinoscopy to identify a source of bleeding after removal of any blood clot (if present) for patients with nosebleeds. (7a) The clinician should perform, or should refer to a clinician who can perform, nasal endoscopy to identify the site of bleeding and guide further management in patients with recurrent nasal bleeding, despite prior treatment with packing or cautery, or with recurrent unilateral nasal bleeding. (8) The clinician should treat patients with an identified site of bleeding with an appropriate intervention, which may include one or more of the following: topical vasoconstrictors, nasal cautery, and moisturizing or lubricating agents. (9) When nasal cautery is chosen for treatment, the clinician should anesthetize the bleeding site and restrict application of cautery only to the active or suspected site(s) of bleeding. (10) The clinician should evaluate, or refer to a clinician who can evaluate, candidacy for surgical arterial ligation or endovascular embolization for patients with persistent or recurrent bleeding not controlled by packing or nasal cauterization. (11) In the absence of life-threatening bleeding, the clinician should initiate first-line treatments prior to transfusion, reversal of anticoagulation, or withdrawal of anticoagulation/antiplatelet medications for patients using these medications. (12) The clinician should assess, or refer to a specialist who can assess, the presence of nasal telangiectasias and/or oral mucosal telangiectasias in patients who have a history of recurrent bilateral nosebleeds or a family history of recurrent nosebleeds to diagnose hereditary hemorrhagic telangiectasia syndrome. (13) The clinician should educate patients with nosebleeds and their caregivers about preventive measures for nosebleeds, home treatment for nosebleeds, and indications to seek additional medical care. (14) The clinician or designee should document the outcome of intervention within 30 days or document transition of care in patients who had a nosebleed treated with nonresorbable packing, surgery, or arterial ligation/embolization. The policy level for the following recommendation, about examination of the nasal cavity and nasopharynx using nasal endoscopy, was an option: (7b) The clinician may perform, or may refer to a clinician who can perform, nasal endoscopy to examine the nasal cavity and nasopharynx in patients with epistaxis that is difficult to control or when there is concern for unrecognized pathology contributing to epistaxis.

Abstract:Blue rubber bleb nevus syndrome (BRBNS), or Bean's syndrome, is a rare angiomatosis characterized by distinctive cutaneous and gastrointestinal venous malformations that usually cause massive or occult gastrointestinal hemorrhage and iron deficiency anemia secondary to the bleeding episodes. Other organs may also be involved. We report a case with symptoms of recurrent epistaxis and chronic gastrointestinal hemorrhage. We hope to emphasize the possibility of recurrent epistaxis involvement in BRBNS and heighten physicians’ awareness of the disease to contribute its early detection. CASE REPORT A 19-year-old man was admitted to our hospital on December 22, 2005 with recurrent epistaxis for 16 years and with melena for 3 months. He was born with a walnut-sized cutaneous angioma on his right forehead, which had been growing as he grew older. When he was four years old, the angioma was surgically resected. As the angioma increased in size with age, he underwent a second operation when he was 10 years old. The patient had experienced epistaxis episodes many times since 3 years of age and the blood loss was so severe that each time it had to be treated by pressure with gauze for an extended period. Unfortunately the family could not provide an accurate history for this condition and the cause was unclear. At admission, the patient experienced epistaxis episodes again and the rhinoscopy showed apparently dilated blood vessels in right nostril (Fig. 1A). By the age of 15, a diagnosis of iron deficiency anemia was made and he has used an oral iron supplementation since then. Three months ago he experienced melena but it was not severe so he did not go to hospital. Recently, the symptoms reappeared. Two months previous to coming to our hospital, he was treated in a local government hospital with an endoscopic procedure for a colonic angioma which had developed into melena. Histological examination showed a cavernous hemangioma. Because his bleeding episodes did not subside after that treatment, he came to our hospital for further diagnosis and treatment.Fig. 1. A:: Dilated blood vessels in right nostril. B: Colonoscopy view: venous malformation in the distal ileum (approximately 1.5 cm×1.5 cm).Fig. 2. A: Capsule endoscopy view: venous malformation in the small bowel (approximately 2.5 cm×3.0 cm). B: Histologic appearance shows some dilated blood vessels, part of which engorged with blood cells (hematoxylin and eosin stain, original magnification×20).Physical examination: an extremely pale face and an elevated bluish lesion with a rubbery consistency on the right forehead of approximately 3.0 cm ×2.5 cm. There were two incision scars on the right forehead. Laboratory findings: a hemoglobin level of 47 g/L, hematocrit of 17.3%, mean corpuscular volume of 75.5 μm3, mean corpuscular hemoglobin of 20.5 pg, mean corpuscular hemoglobin concentration of 272 g/L, and red blood cell distribution width of 21.6%. On the peripheral blood smear, the red blood cells were microcytic and hypochromic, indicating an iron deficiency anemia. To clarify the causes of gastrointestinal hemorrhage, a colonoscopy was performed, which showed a bluish vascular lesion of 1.5 cm×1.5 cm, with a bloodstain in the distal ileum (Fig. 1B). To check for the possibility of the presence of any nevus besides cutaneous and colonic lesions, a capsule endoscopy was done. Four indigo vascular lesions were discovered with the largest one measuring approximately 2.5 cm×3.0 cm in diameter (Fig. 2A). To control the condition and to prevent massive hemorrhage, the patient was operated and five bluish vascular lesions were found in the small intestine with the largest being approximately 2.5 cm×3.0 cm in diameter. The pathological study of the surgical specimens showed multiple dilated blood vessels, some of which were engorged with red blood cells residing on the submucosa (Fig. 2B). BRBNS lesions were soft, blue nodules comprised of dysplastic venous channels with flat endothelium and irregularly attenuated walls with deficient smooth muscle cells. The diagnosis of the venous malformations was compatible with BRBNS. After the operation, the patient made a quick recovery. Melena was controlled and he did not experience any more epistaxis. DISCUSSION BRBNS was probably first observed by Gascoyen in 1860.1 A century later, Bean2 coined the term blue rubber bleb nevus syndrome for this rare disorder which is characterized by vascular malformations of the skin and viscera, especially in the gastrointestinal tract. Approximately 150 cases of the BRBNS have since been reported.3 The typical symptom of this disease is venous malformations, which are present at birth or may appear in childhood and increase in size and number with age.4,5 Skin lesions are usually highly characteristic as multiple, protuberant, bluish, compressible blebs, a few millimeters to several centimeters in diameter and varied in shape. Most of these are asymptomatic but some may be spontaneously painful or tender when palpated. Skin lesions rarely bleed unless traumatized. Gastrointestinal system involvement usually becomes evident during early adulthood. Venous malformations may occur anywhere from oral to anal mucosa but predominantly occurs in the small bowel.3,6,7 In contrast to the skin lesions, the gastrointestinal lesions tend to bleed easily, leading to massive hemorrhage and iron deficiency anemia that may be severe and require blood transfusions and iron supplementation. Endoscopic evaluation of the gastrointestinal system is probably the ideal modality to diagnose gastrointestinal system venous malformations. In the case above, colonoscopy and capsule endoscopy revealed multiple venous malformations in the jejunum, ileum and colon. Blue rubber bleb nevus have also been reported in the nasopharynx, eyes, thyroids, parotids, central nervous system, skeletal muscles, pleura, peritoneum, pericardium, mesentery, lungs, kidneys, liver, spleen, penis, vulva and bladder.8 Systemic complications may also occur in these patients, such as thrombosis and calcification. In addition, patients suffer from consumptive coagulopathy, thrombocytopenia, Maffucci syndrome, and chronic lymphocytic leukemia that may occur within the nevus.3,9 In our report, the patient experienced recurrent epistaxis and the cause was not determined until the rhinoscopy revealed that some blood vessels were dilated within the mucosa of the right nostril. According to a Medline search, this is one of few case reports of BRBNS with epistaxis. It tells us that early detection of this condition is important because it alerts the physician to the possibility of associated bleeding, anemia, and other systemic complications that may occur. Our experience suggests that it is essential to bear in mind the possibility that venous malformation may occur in other organs. Early diagnosis is important because of the potential for serious or fatal bleeding. Diagnosis can be established by endoscopy in time. Soft tissue masses not specific for hemangiomas can be revealed by CT scans and selective arteriography and scintillography are useful in cases of active bleeding.4,10 The management of skin lesions in BRBNS is limited to surgical excision or laser ablation. Treatment of gastrointestinal lesions varies according to their extent, location, and consequences. For patients with small numbers of lesions or with lesions that are too diffuse and who have anemia without open bleeding, elective transfusions and iron replacement are recommended. For more significant hemorrhages, surgical resection, endoscopic sclerosis, band ligation, laser photocoagulation, and therapy with interferon are proposed.3,11–16 Although rarely mentioned in the literature, corticosteroids, interferon-α, and vincristine have been tried in some patients, but the lesions returned to their pretreatment levels soon after the treatment discontinued.6,17 Our patient was treated by surgical resection of the angiomas and the intestinal anastomosis according to his condition. After the operation, the bleeding episodes were controlled. The syndrome's most common presentation is in the form of sporadic cases, but it can be inherited as an autosomal dominant trait. Recent analysis has identified a locus on chromosome 9 responsible for venous malformations.18 Because its pathogenesis is not yet clear, further research should be done on the pathogenesis of the disease to discover the best treatment modalities for the disease. In the present account, we give an overview of the clinical features, diagnosis methods, and therapeutic options of BRBNS. This report underlines the need for endoscopy in young patients with a long history of epistaxis and gastrointestinal hemorrhage. Besides, it will heighten physicians’ awareness of the disease in the hope of contributing to its early detection.

A 3-Year-old Girl with Frequent Nose Bleeds.

Etiology and Clinical Characteristics of Primary Epistaxis.

Kaposiform Hemangioendothelioma Presented with Raynaud Phenomenon: a Case Report

Aberrant Expression of NLRP3, NLRC4 and NLRP6 Inflammasomes in Patients with Primary Immune Thrombocytopenia

Analysis of Risk Factors and Development of Scoring System to Predict Severity of Upper Gastrointestinal Bleeding in Children

Clinical analysis on Glanzman Thrombasthenia with epistaxis first complaint：three cases report and foreign literature review

A splice mutation in RASGRP2 gene in the patient with recurrent epistaxis and nasal vascular malformation

A case of acquired transient bleeding diathesis associated with acquired platelet storage pool deficiency and defective thromboxane A2 production

Managing recurrent nosebleeds in children: a retrospective review of 718 children attending a nurse-led epistaxis clinic

Clinical Practice Guideline: Nosebleed (Epistaxis)

Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary

Age-related clinical characteristics and differences of refractory nasal bleeding site

Environmental impact on pediatric epistaxis and the utility of diagnostic studies: A single-institutional review

Blue Rubber Bleb Nevus Syndrome: a Report of One Case Associated with Recurrent Epistaxis.

Neonatal Hemophilia: A Rare Presentation

Recurrent Petechia and Epistaxis in a Patient Diagnosed As Diabetes Mellitus for 2 Years

Epidemiological characteristics and clinical analysis of refractory epistaxis

Sudden Convulsion with Multiple Pulmonary Nodules in a Girl Aged 15 Years

Retinal hemorrhage and bleeding disorders in children: A review

Severe haemophilia a in a preterm girl with turner syndrome - a case report from the prenatal period to early infancy (part I)

Heterozygous ITGA2B Phe1024 Deletion Associated with Abnormal αIIbβ3 Function in a Patient with Congenital Thrombocytopenia